Explore the vast range of titles available.

The wake behavior of wind turbines in complex terrain is influenced by the combined effects of atmospheric turbulence and terrain features, which brings challenges to wind farm power production and safety. Despite extensive studies, there remains a gap in understanding the combined impact of turbulent inflows and terrain slopes on turbine wake behaviors. To address this, the current study conducted systematic wind tunnel experiments, using scaled wind turbines and terrain models featured both gentle and steep slopes. In the experiments, different turbulent inflows were generated and the wake characteristics of turbines located at different locations were analyzed. The results demonstrated that higher turbulence intensity accelerates wake recovery, and that steep slopes introduce distinctive wake patterns, including multi-peak added turbulence intensity profiles. Moreover, turbines on hilltops exhibited a more rapid wake recovery compared to those positioned in front of hills, a phenomenon attributed to the influence of adverse pressure gradients. This study provides pivotal experimental insights into the evolution laws of wind turbine wake over terrains under different turbulent inflow conditions, which are instrumental in wind turbine siting in complex terrains.

Establishing a valid in vitro model to represent tumor heterogeneity and biology is critical but challenging. Tumor organoids are self‐assembled three‐dimensional cell clusters which are of great significance for recapitulating the histopathological, genetic, and phenotypic characteristics of primary tissues. The organoid has emerged as an attractive in vitro platform for tumor biology research and high‐throughput drug screening in cancer medicine. Organoids offer unique advantages over cell lines and patient‐derived xenograft models, but there are no standardized methods to guide the culture of organoids, leading to confusion in organoid studies that may affect accurate judgments of tumor biology. This review summarizes the shortcomings of current organoid culture methods, presents the latest research findings on organoid standardization, and proposes an outlook for organoid modeling.

Deep-sea chemosynthetic ecosystems, including cold seeps and hydrothermal vents, are widely spread in global oceans. Campylobacterota are important primary producers in deep-sea hydrothermal vents and serve as a vital food source for local invertebrates. However, the nutrients that these bacteria can provide to their hosts are unclear. To date, research on Campylobacterota in cold seeps is very limited. Consequently, little is known about the biological features and ecological potential of Campylobacterota in cold seeps. In the present work, we examined the diversity, growth, metabolic characteristics, and nutrient production of Campylobacterota in a deep-sea cold seep. Over 1000 Campylobacterota ASVs, especially autotrophic and , were identified. By optimizing the culture medium, 9 and strains were isolated, including three potentially novel species. Two novel species were characterized and found to exhibit unique morphological features. These two novel strains possessed complete reverse tricarboxylic acid pathways. One novel strain, FCS5, was a psychrotolerant autotroph with denitrification and phosphorus-removing capacity. FCS5 could grow in the absence of vitamins. Consistently, metabolomics and transcriptome analyses indicated that FCS5 produced multiple vitamins, which regulated the expressions of a large number of genes associated with carbon fixation and multiple-nutrient synthesis. Besides vitamins, autotrophic Campylobacterota also produced abundant free amino acids, fatty acids (short-chain, medium, and long-chain), and proteins. This study indicates that the cold seep abounds with Campylobacterota, which are capable of providing various nutrients for the chemosynthetic ecosystem. In addition, these bacteria may have wide applications, such as in wastewater treatment and carbon emission reduction.

BackgroundThe clinicopathology of aneurysmal bone cysts (ABCs) secondary to osteosarcoma has not yet been reported. We conduct a retrospective review of ABCs secondary to osteosarcoma to characterize clinicopathology and influence on the survival of patients with Enneking stage IIB extremity osteosarcoma.Patients and MethodsA total of 300 patients with Enneking stage IIB extremity osteosarcoma were eligible for analysis. These cases were divided, according to the pathology of biopsy and magnetic resonance imaging (MRI), into ABCs group and no ABCs group. Patients (ABCs versus no ABCs) were compared using a 1:2 propensity score analysis to best match between groups. Clinicopathology and survival data were analyzed.ResultsThe total occurrence rate of secondary ABCs was 10.3%. A higher prevalence of pathological fractures was observed in the ABCs group (22.6%) compared with the no ABCs group (8.6%) (p = 0.032). Patients with ABCs were more likely to undergo amputation compared with patients without ABCs (p = 0.007). Those with secondary ABCs had poorer response to chemotherapy before and after propensity score matching (p = 0.006 and p = 0.048, respectively). Kaplan–Meier survival analysis showed that EFS and OS distributions were not significantly different between the two patient groups. ABCs were not significantly different in terms of EFS or OS in the multivariate analysis model (p > 0.05).ConclusionsThe presence of secondary ABCs was associated with increased occurrence rate of pathological fracture and high percentage of amputation. Moreover, patients with secondary ABCs had poorer response to chemotherapy. However, the presence of secondary ABCs did not influence survival of patients with Enneking stage IIB extremity osteosarcoma.

The International Energy Agency (IEA), under the auspices of their Offshore Code Comparison Collaboration (OC3) initiative, has completed high-level design OC-3 Hywind system. In this system the wind turbine is supported by a spar buoy platform, showing good wave-resistance performance. However, there are still large values in the motion of surge degree of freedom (DOF). Addition of clump masses on the mooring lines is an effective way of reducing the surge motion. However, the optimization of the locations where the clump masses are added is still not clear. In this study, therefore, an in-house developed code is verified by comparing the results of the original OC3 model with those by FAST. The improvement of the performance of this modified platform as a function of the location of the clump masses has been examined under three regular waves and three irregular waves. In the findings of these examination, it was apparent that attaching clump masses with only one-tenth of the mass of the total mooring-line effectively reduces the wave-induced response. Moreover, there is an obvious improvement as the depth of the location where the clump masses mounted is increased.

Background The purpose of this study was to evaluate the efficacy and safety of fruquintinib‐based therapy as a salvage therapy for patients with advanced or metastatic sarcoma, including soft tissue sarcoma (STS) and bone sarcoma. Methods Patients with advanced or metastatic sarcoma were divided into two groups. One group received fruquintinib monotherapy, while the other received fruquintinib combined therapy. Safety and efficacy of fruquintinib‐based therapy were recorded and reviewed retrospectively, including progression‐free survival (PFS), overall response rate (ORR), and adverse events (AEs). Results Between August 2021 and December 2022, 38 sarcoma patients were retrospectively included. A total of 14 patients received fruquintinib alone (including 6 STS and 8 bone sarcoma), while 24 were treated with fruquintinib combined therapy (including 2 STS and 22 bone sarcoma). The median follow‐up was 10.2 months (95% CI, 6.4–11.5). For the entire population, the median PFS was 8.0 months (95% CI, 5.5–13.0). The ORR was 13.1%, while the disease control rate (DCR) was 86.8%. The univariate analysis showed that radiotherapy history (HR, 4.56; 95% CI, 1.70–12.24; p = 0.003), bone sarcoma (HR, 0.34; 95% CI, 0.14–0.87; p = 0.024), and treatment method of fruquintinib (HR, 0.36; 95% CI, 0.15–0.85; p = 0.021) were significantly associated with PFS. The multivariate analysis showed that patients without radiotherapy history were associated with a better PFS (HR, 3.71; 95% CI: 1.31–10.55; p = 0.014) than patients with radiotherapy history. Patients in combination group reported pneumothorax (8.3%), leukopenia (33.3%), thrombocytopenia (12.5%), diarrhea (4.2%), and anemia (4.2%) as the most frequent grade 3 or higher treatment‐emergent AEs (TEAEs), while there was no severe TEAEs occurred in the monotherapy group. Conclusions Fruquintinib‐based therapy displayed an optimal tumor control and an acceptable safety profile in patients with advanced or metastatic sarcoma.

DeepCwind semi-submersible floating offshore wind turbines have been widely examined, and in some countries this type of floating offshore wind turbine has been adopted in the construction of floating wind farms. However, the DeepCwind semi-submersible floating offshore wind turbines still experience large surge motion that limits their operational time. Therefore, in this study, a semi-submersible floating platform with different numbers of offset columns, but with the same total weight, based on the DeepCwind prototype is proposed. From the free-decay test, it was found that the number of the floating columns will affect the natural frequency of the platform. Furthermore, the regular wave test in the time domain and the irregular wave test in the frequency domain show that increasing the number of the floating columns will reduce the surge motion greatly, while the effects in the heave and pitch motions are not obvious.

Improving the accuracy of short-term wind speed predictions is crucial for mitigating the impact on power systems when integrating wind power into an electricity grid. This study developed a hybrid short-term wind speed prediction method, termed VMD–SSA–GRU, by combining variational mode decomposition (VMD) with gated recurrent units (GRUs) and optimizing it using a sparrow search algorithm (SSA). Initially, VMD was used to decompose the wind speed time series into subtime series. After reconstructing these subtime series, a GRU model was employed to establish separate prediction models for each series. Furthermore, an enhanced SSA was proposed to optimize the hyperparameters of the GRU model, which improved the prediction accuracy. Ultimately, the sub-series predictions were aggregated to produce the final wind speed prediction values. The predictive accuracy of this model was validated using the wind speed data measured at a meteorological station near a bridge site. The performance of the VMD–SSA–GRU model was compared with several other hybrid models, including those using wavelet transform, long short-term memory, and other neural networks. Comparably, the RMSE value of the VMD-SSA-GRU model was lower by 25.3%, 60.2%, and 61.7% in comparison to the VMD–SSA–LSTM, VMD–GRU, and VMD–LSTM models, respectively. The experimental results demonstrated that the proposed method achieved higher prediction accuracy than traditional methods.

Purpose: The options for the second-line treatment of metastatic osteosarcoma are still limited. Anlotinib is a multi-kinase inhibitor which has shown promising efficacy and good tolerability in various cancer types. This retrospective study was conducted to evaluate the efficacy and safety of anlotinib combined with gemcitabine/docetaxel (GD) in patients with metastatic osteosarcoma who have failed first-line chemotherapy. Patients and Methods: The data of patients who received anlotinib combined with GD or GD were collected. The primary endpoint was progression-free survival. Secondary endpoints included objective response rate and safety. Results: From July 2013 to November 2020, a total of 32 patients were enrolled, 13 received anlotinib combined with GD and 19 received GD. Median PFS was 9.0 months (95% CI 6.7-39.1) in the combination group and 5.0 months (95% CI 1.2-6.7) in the chemotherapy group. ORR were 38.4% and 15.8%, DCR were 69.2% and 38.1% in the combination and chemotherapy group, respectively. The most common adverse events included fatigue (78.9% in the combination group vs 69.2% in the chemotherapy group), hypertension (46.2% vs 10.5%), diarrhea (38.5% vs 21.1%), hypothyroidism (38.5% vs 15.8%), neutropenia (23.1% vs 36.8%) and AST elevation (30.8% vs 21.1%). The most common grade 3 or worse adverse events included hand-foot reaction (7.7% vs 5.3%), hypothyroidism (15.4% vs 0), neutropenia (0 vs 10.5%). Conclusion: The combination of anlotinib and GD showed favorable efficacy with manageable toxicities compared with GD in the second-line treatment for metastatic osteosarcoma. This combination therapy deserves further investigations in patients with osteosarcoma. Keywords: anlotinib, refractory metastatic osteosarcoma, combination therapy

Inflammatory response and nutritional status are associated with cancer development and progression. The present study aimed to evaluate the predictive ability of the fibrinogen-albumin ratio index (FARI) to the efficacy of neoadjuvant chemotherapy (NAC) for osteosarcoma. A retrospective analysis involving 752 consecutive osteosarcoma patients between 2012 and 2020 was performed. Data on serum fibrinogen, albumin levels, white blood cell count, platelet count, and alkaline phosphatase (ALP) before and after NAC were collected. The predictive value of the NAC efficacy in osteosarcoma was assessed by constructing a receiver operating characteristic (ROC) curve and calculating the area under the curve (AUC). Prognosis and its predictive factors were analyzed by Kaplan-Meier method and COX regression analysis. Nomogram was established according to selected variables. The predictive performance of the nomogram model was assessed using C-statistics. A total of 203 patients were included. ROC analysis showed that both FARI before NAC (preFARI; AUC = 0.594, = 0.032) and the change in FARI before and after NAC (dfFARI = preFARI-postFARI; AUC = 0.652, = 0.001) exhibited more favorable predictive ability than ALP and other inflammation markers. The preFARI was divided into the high group (>6.1%) and the low group (≤6.1%) based on the optimal cut-off value of 6.1%. Patients with a high preFARI showed significantly decreased metastasis-free survival (MFS) and disease-free survival (DFS) (all <0.01). In multivariable analysis, preFARI was an independent prognostic marker for patients with osteosarcoma. Predictive nomograms exhibited good ability to predict MFS (C-index = 0.748, se = 0.028) and DFS (C-index=0.727, se = 0.030). Our findings indicated that FARI exhibits the favorable predictive ability for the efficacy of NAC for osteosarcoma, which could support clinicians and patients in clinical decision-making and treatment optimization.